What is the management plan for a patient on Eliquis (apixaban), Brilinta (ticagrelor), and aspirin for conditions like atrial fibrillation or acute coronary syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 2, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Guidelines

The management of a patient on triple antithrombotic therapy with Eliquis (apixaban), Brilinta (ticagrelor), and aspirin requires careful monitoring and typically time-limited use due to bleeding risks, with a recommended duration of 1-6 months depending on the patient's specific condition and bleeding risk. For patients with both atrial fibrillation and recent acute coronary syndrome or stent placement, consider transitioning to dual therapy (typically an anticoagulant plus a single antiplatelet) after the initial high-risk period, as supported by the 2021 ACC expert consensus decision pathway 1. Standard dosing includes apixaban 5mg twice daily (or 2.5mg twice daily for patients meeting dose reduction criteria), ticagrelor 90mg twice daily, and aspirin 81mg daily.

Key Considerations

  • Regular monitoring should include complete blood counts, renal function, and clinical assessment for bleeding, as bleeding risks are significantly increased with triple antithrombotic therapy 1.
  • Patients should be educated about bleeding signs and instructed to seek immediate medical attention for significant bleeding events.
  • The decision to extend or shorten the duration of triple antithrombotic therapy should be based on the individual patient's thrombotic versus hemorrhagic risk profile, with consideration of factors such as the presence of atrial fibrillation, acute coronary syndrome, or stent placement, as well as the patient's bleeding risk factors.

Treatment Duration

  • For patients at high ischemic/thrombotic risk and low bleeding risk, triple therapy may be continued for up to 1 month after PCI, as suggested by the 2018 North American expert consensus update 2.
  • For patients at low ischemic/thrombotic risk or high bleeding risk, consider discontinuing aspirin and transitioning to dual therapy with an anticoagulant and a single antiplatelet agent after the initial high-risk period.
  • The ultimate goal is to balance the need to prevent stroke in atrial fibrillation and stent thrombosis while minimizing the risk of bleeding complications, as emphasized by the 2021 ACC expert consensus decision pathway 1.

From the FDA Drug Label

7.3 Anticoagulants and Antiplatelet Agents Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk, post-acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo. In ARISTOTLE, concomitant use of aspirin increased the bleeding risk on apixaban from 1.8% per year to 3.4% per year and concomitant use of aspirin and warfarin increased the bleeding risk from 2.7% per year to 4.6% per year.

The management plan for a patient on Eliquis (apixaban), Brilinta (ticagrelor), and aspirin for conditions like atrial fibrillation or acute coronary syndrome should focus on bleeding risk management.

  • Key considerations:
    • The patient is at an increased risk of bleeding due to the concomitant use of antiplatelet agents (aspirin and ticagrelor) and an anticoagulant (apixaban).
    • The risk of bleeding should be carefully weighed against the benefits of anticoagulation and antiplatelet therapy.
    • Regular monitoring of the patient's bleeding risk and adjustment of the treatment plan as needed is crucial.
    • Patients should be educated on the signs and symptoms of bleeding and the importance of seeking immediate medical attention if they occur.
    • The use of apixaban with aspirin and ticagrelor should be carefully managed, and the patient should be closely monitored for signs of bleeding 3.

From the Research

Management Plan for Patients on Eliquis, Brilinta, and Aspirin

The management plan for patients taking Eliquis (apixaban), Brilinta (ticagrelor), and aspirin for conditions like atrial fibrillation or acute coronary syndrome involves careful consideration of the benefits and risks of antithrombotic therapy.

  • The combination of anticoagulant and antiplatelet therapy is more effective than antiplatelet therapy alone for the initial and long-term management of acute coronary syndromes, but it increases the risk of bleeding 4.
  • Apixaban has been shown to significantly reduce the risk of total bleeding compared to vitamin K antagonists (VKA) in patients with atrial fibrillation and recent acute coronary syndrome or percutaneous coronary intervention 5.
  • Aspirin has been found to double the total bleeding risk compared to placebo without a significant change in total ischemic events in patients with atrial fibrillation and recent acute coronary syndrome or percutaneous coronary intervention 5.

Antithrombotic Regimens

The choice of antithrombotic regimen depends on various factors, including the patient's risk of bleeding and ischemic events.

  • The use of apixaban plus a P2Y12 inhibitor (e.g., clopidogrel) without aspirin is supported as the standard therapy for patients with atrial fibrillation and recent acute coronary syndrome or percutaneous coronary intervention 5, 6.
  • Dabigatran dual therapy with ticagrelor or clopidogrel has been evaluated in patients with atrial fibrillation after percutaneous coronary intervention, and the results suggest that dabigatran dual therapy reduces the risk of major or clinically relevant non-major bleeding events compared to warfarin triple therapy 7.

Risk/Benefit Tradeoff

The risk/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention should be carefully considered.

  • Apixaban has been shown to have a lower or similar risk of bleeding and ischemic outcomes compared to VKA from randomization to 30 days and from 30 days to 6 months 8.
  • Aspirin has been found to cause more severe bleeding and fewer severe ischemic events than placebo from randomization to 30 days, but the risk of severe bleeding remains higher with aspirin than placebo from 30 days to 6 months, without a significant reduction in severe ischemic events 8.

References

Research

Combined antiplatelet and anticoagulant therapy: clinical benefits and risks.

Journal of thrombosis and haemostasis : JTH, 2007

Related Questions

What is the recommended antithrombotic therapy (apixaban, aspirin, and clopidogrel) for a patient with acute myocardial infarction and atrial fibrillation?
For an 85-year-old female with no bleeding history who is on clopidogrel after percutaneous coronary intervention and now has atrial fibrillation, should she be treated with apixaban (Eliquis) and continue clopidogrel, and what is the appropriate antithrombotic regimen?
What are the first-line treatment options for patients requiring anti-platelet (anti-thrombotic) therapy?
What is the difference between antiplatelet and anticoagulant therapy in clinical practice?
What is the appropriate management for an 80-year-old woman with sepsis secondary to urinary tract infection (UTI), nephrolithiasis of the right ureter with hydronephrosis, and complications including recurrent hypothermia, bradycardia, and encephalopathy?
What is a suitable alternative to Etoricoxib (Arcoxia) for a patient in Canada?
Does oral magnesium interact with statin (HMG-CoA reductase inhibitor) medications, such as atorvastatin (Lipitor) or simvastatin (Zocor), and affect their efficacy or increase the risk of adverse effects like muscle cramps or weakness?
What is the proper technique for lymph node examination?
What is the growth rate and management plan for vestibular (acoustic neuroma) schwannomas?
What is the recommended treatment for a urinary tract infection caused by Methicillin-Sensitive Staphylococcus aureus (MSSA)?
How does tolterodine (antimuscarinic) affect patients with Impaired renal function (IRF)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.